Avinger Regains Compliance with Nasdaq Listing Requirements

Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) announced it has regained compliance with Nasdaq listing requirements as of January 26, 2021. This compliance relates to the minimum bid price rule necessary for continued listing on the Nasdaq Capital Market. Avinger specializes in innovative medical devices for the diagnosis and treatment of Peripheral Artery Disease (PAD), a condition affecting over 12 million people in the U.S. and more than 200 million globally. The company's Lumivascular platform includes advanced imaging and catheter technologies.

Positive

• Regained compliance with Nasdaq listing requirements.
• Innovative medical device company with a unique product offering for PAD.

Negative

• None.

REDWOOD CITY, CA / ACCESSWIRE / January 27, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has regained compliance with Nasdaq listing requirements.

In a letter dated January 26, 2021, Nasdaq informed the Company that it has achieved compliance with the minimum bid price rule required for continued listing on the Nasdaq Capital Market.

About Avinger, Inc.

Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Investor Contact:
Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

SOURCE: Avinger, Inc.

View source version on accesswire.com:
https://www.accesswire.com/626167/Avinger-Regains-Compliance-with-Nasdaq-Listing-Requirements

FAQ

What did Avinger announce on January 27, 2021?

Avinger announced it has regained compliance with Nasdaq listing requirements.

What is the stock symbol for Avinger?

The stock symbol for Avinger is AVGR.

Why is Avinger's compliance with Nasdaq important?

Compliance is crucial for maintaining its listing on the Nasdaq Capital Market and ensuring investor confidence.

What condition does Avinger's technology address?

Avinger's technology addresses Peripheral Artery Disease (PAD), affecting over 12 million people in the U.S.

What technologies are part of Avinger's Lumivascular platform?

The Lumivascular platform includes the Lightbox imaging console and various catheter systems for PAD treatment.